/
NKTR
$63.34-$0.31 (-0.49%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.2B
34M shares
52-week range
$21.02 – $109.00
48% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.26%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-194.06
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.19B | $114.6M | $152.9M | $101.9M | $92.1M | $90.1M | $98.4M | $55.2M |
| Cost of revenue | $24.4M | $21.4M | $19.5M | $24.9M | $21.6M | $36.6M | $30.7M | $0 |
| Gross profit | $1.17B | $93.2M | $133.4M | $77.0M | $70.4M | $53.5M | $67.7M | $55.2M |
| Gross margin | 98.0% | 81.4% | 87.3% | 75.6% | 76.5% | 59.3% | 68.8% | 100.0% |
| R&D | $399.5M | $434.6M | $408.7M | $400.3M | $218.3M | $114.2M | $120.9M | $117.3M |
| Operating income | $687.9M | −$440.0M | −$379.9M | −$446.1M | −$240.2M | −$137.4M | −$105.2M | −$130.8M |
| EBITDA | $734.3M | −$382.7M | −$394.3M | −$461.8M | −$323.9M | −$243.1M | −$86.7M | −$137.0M |
| Net income | $681.3M | −$440.7M | −$444.4M | −$523.8M | −$368.2M | −$276.1M | −$119.0M | −$164.1M |
| Net margin | 57.1% | -384.5% | -290.6% | -514.0% | -400.0% | -306.3% | -120.9% | -297.1% |
| EPS (diluted) | 56.70 | -37.80 | -37.33 | -42.90 | -29.51 | -21.79 | -8.68 | -9.73 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $41M | $-9.06 | $-10.57–$-7.33 | 7 |
| 2027 | $37M | $-11.07 | $-13.23–$-6.48 | 7 |
| 2028 | $52M | $-11.40 | $-14.32–$-7.33 | 9 |
| 2029 | $95M | $-10.61 | $-12.17–$-5.03 | 3 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
www.nektar.com- Employees
- 63
- IPO / List date
- May 3, 1994
- HQ
- SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds NKTR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 41,781 | $3.0M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-06-09 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded NKTR yet.
